Showing results (1-10 of 37) with videos related to
Sort By:
Pageof 4
Hematology. American Society of Hematology. Education Program|December 6, 2015
Management of symptoms in polycythemia vera and essential thrombocythemia patientsDeepti Radia, Holly L GeyerHematology. American Society of Hematology. Education Program|February 20, 2015
Therapy for myeloproliferative neoplasms: when, which agent, and how?Holly L Geyer, Ruben A MesaBlood|December 5, 2014
Therapy for myeloproliferative neoplasms: when, which agent, and how?Holly L Geyer, Ruben A MesaExpert Opinion on Emerging Drugs|July 9, 2015
Emerging drugs for the treatment of myelofibrosisHolly L Geyer, Ruben A MesaBlood|May 1, 2020
How I treat pain in hematologic malignancies safely with opioid therapyHolly L Geyer, Halena Gazelka, Ruben MesaHematology (Amsterdam, Netherlands)|April 18, 2012
JAK2 inhibitors and their impact in myeloproliferative neoplasmsHolly L Geyer, Raoul Tibes, Ruben A MesaJRSM Open|July 28, 2017
A case of hypercalcaemia in an immunocompetent patient with Mycobacterium avium intracellulareChristine E Parsons, Sujata Singh, Holly L GeyerCurrent Hematologic Malignancy Reports|September 29, 2014
Quality of life in MPN comes of age as a therapeutic targetRobyn M Scherber, Holly L Geyer, Ruben A MesaLeukemia & Lymphoma|February 4, 2015
Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitorsRuben A Mesa, Robyn M Scherber, Holly L GeyerAnnals of Hematology|January 30, 2019
Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient surveyJingbo Yu, Dilan Paranagama, Holly L Geyer, et al.Pageof 4